Help is a sufficiently vague term that your proposed question about Teva’s outside help is not especially helpful for investors, IMO. What I’m laying on the table for consideration is the possibility that Teva may have gotten its entire Lovenox drug candidate—hook, line, and sinker—from a third party.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”